Shares of Corcept Therapeutics Inc. (NASDAQ:CORT) rose 2.6% during mid-day trading on Monday . The stock traded as high as $6.01 and last traded at $5.88, with a volume of 126,887 shares changing hands. The stock had previously closed at $5.73.

CORT has been the subject of several recent research reports. Zacks Investment Research downgraded Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 30th. FBR & Co restated an “outperform” rating and issued a $12.00 price target on shares of Corcept Therapeutics in a research note on Thursday, June 23rd.

The company’s market capitalization is $623.64 million. The firm’s 50 day moving average price is $5.63 and its 200-day moving average price is $4.68.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, May 3rd. The company reported $0.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.01. The company earned $16.10 million during the quarter, compared to the consensus estimate of $16.32 million. Analysts anticipate that Corcept Therapeutics Inc. will post $0.04 earnings per share for the current year.

In related news, Director G Leonard Baker, Jr. bought 100,000 shares of the company’s stock in a transaction dated Tuesday, May 10th. The shares were bought at an average price of $4.88 per share, for a total transaction of $488,000.00. Following the completion of the acquisition, the director now directly owns 721,038 shares of the company’s stock, valued at $3,518,665.44. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

An institutional investor recently raised its position in Corcept Therapeutics stock. Globeflex Capital L P raised its position in shares of Corcept Therapeutics Inc. (NASDAQ:CORT) by 164.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 244,301 shares of the company’s stock after buying an additional 151,869 shares during the period. Globeflex Capital L P owned 0.22% of Corcept Therapeutics worth $1,217,000 as of its most recent SEC filing.

Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.